Evidence map›Paper›PMID 36618974›Full record

ReviewNew microbes and new infections2023

The global case fatality rate due to COVID-19 in hospitalized elderly patients by sex, year, gross domestic product, and continent: A systematic review, meta-analysis, and meta-regression.

Elham Davtalab Esmaeili, Hosein Azizi, Ehsan Sarbazi, Farzad Khodamoradi

Registry-linked trialAbstract readReview
In one paragraph

Review in New microbes and new infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07527247 (Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity), which is not on this map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07527247 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity

TypeinterventionalSponsorSingapore General HospitalRan2025 to 2029Enrolled40ConditionsImmune System Responses and Trained Immunity After AS01 Administration, Healthy AdultArmsAS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
    Article
  6. Article
  7. Altitude and case fatality rate from COVID-19 during the pandemic in Peru, 2020-2022.Revista peruana de medicina experimental y salud publica · 2026
    Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elham Davtalab EsmaeiliStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Hosein AziziResearch Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Ehsan SarbaziRoad Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Farzad KhodamoradiDepartment of Social Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although elderly people are at a huge risk of mortality due to COVID-19, the Case Fatality Rate (CFR) in hospitalized elderly patients is poorly investigated. This meta-analysis and meta-regression aimed to generate pooled CFR due to COVID-19 in hospitalized elderly patients by sex, Gross Domestic Product (GDP), year, and continent and also to explain the potential source of the heterogeneity and variations in the pooled estimation of COVID-19 CFR. Methods: We systematically searched PubMed, Scopus, Web of Science, CINAHL, and Embase up to 31 July 2022. Eligibility assessment of records was performed independently in a blinded, standardized way by two reviewers. Meta-analysis and Meta-regression analysis were carried out to estimate pooled CFR and the potential sources of the heterogeneity. Results: The study included 5683 confirmed hospitalized elderly COVID-19 patients, 1809 deaths, and 19 original articles from 10 countries. The pooled estimate of the overall CFR, and by male and female sexes were 29%, 34%, and 24%, respectively. We found CFR was decreased by increasing female sex proportion, GDP, and year of publication. Multivariate meta-regression analysis indicated that the age and sex of patients, continent, GDP, and year of the publication together explained the majority of the heterogeneity and variations in the pooled estimate of the hospitalized elderly COVID-19 CFR. Conclusions: This review provided reliable pooled CFR measures for hospitalized elderly patients with COVID-19. Although COVID-19 fatality has decreased in hospitalized elderly patients over time, it is still high in hospitalized elderly patients and needs advanced treatment support.

Indexed as

COVID-19ElderlyHospitalizedMeta-analysisMortality

Identifiers

PMID36618974
PMCPMC9811917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.